Ravidasvir
Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.[1]
![]() | |
Clinical data | |
---|---|
Other names | PPI-668 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C42H50N8O6 |
Molar mass | 762.912 g·mol−1 |
3D model (JSmol) | |
| |
|
Preliminary clinical trial results were announced in Nov 2015.[2] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[3]
References
- Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
- "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.
- Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.